Why Companies Across Industries Need to Develop a Bio Strategy

Episode Summary

Executive Summary: The interview explores synthetic biology as a field aimed at making biology easier to engineer, comparing its maturation to software engineering. John Cumbers highlights falling DNA sequencing and synthesis costs, the sector’s investment growth, and persistent scale-up/manufacturing challenges. He argues every company needs a bio strategy because biology is increasingly disrupting industries beyond healthcare.

Main Topics: Defining synthetic biology as engineering biology (Priority: 5/5): Cumbers frames synthetic biology as the effort to make biology easier to engineer, similar to how software engineering became more modular and accessible through infrastructure improvements. DNA reading and writing as core growth drivers (Priority: 5/5): He says the biggest gains come from cheaper sequencing (reading DNA) and synthesis (writing DNA), which are enabling broader experimentation and commercialization. Scale-up and manufacturing as a key bottleneck (Priority: 5/5): The discussion emphasizes how fermentation and industrial scale-up remain difficult because biology is complex, poorly standardized, and often protected by trade secrets rather than published science. Investment momentum in synthetic biology (Priority: 4/5): Cumbers points to strong and growing investment in the sector, even amid a wider tech slowdown, as evidence of confidence in commercial potential. Bio strategy as a cross-industry imperative (Priority: 5/5): He argues that companies in consumer goods, materials, food, and industrial sectors must develop a bio strategy or risk disruption from biology-enabled competitors. SynBioBeta conference as a showcase for the field (Priority: 3/5): The conference is presented as a major convening point for investors, scientists, and companies, featuring speakers and examples that demonstrate commercial traction.

Key Arguments: Synthetic biology is fundamentally about making biology easier to engineer, just as software engineering became more manageable through infrastructure and abstraction. The biggest technical breakthroughs are falling costs in DNA sequencing and DNA synthesis, which are accelerating innovation. The major industry challenge is not just invention but reproducible, standardized, and scalable manufacturing. Industrial scale-up is hampered by biological complexity and the fact that much of the practical knowledge is locked away as trade secrets. Investment in synthetic biology has continued to rise despite broader tech-sector softness, suggesting strong market belief in the field. Biology is already enabling products across sectors, so every company should have a bio strategy to avoid disruption.

Data Points: Conference dates: October 3–5 - SynBioBeta conference in San Francisco Conference venue: Mission Bay Conference Center, San Francisco - Location for the SynBioBeta event Funding raised in first six months of 2017: Over $500 million - Cumbers cites the sector's second-quarter update Funding in the prior year: Over $1 billion - Synthetic biology investment the year before Funding two years prior: $800 million - Synthetic biology investment the year before that Funding three years prior: $500 million - Synthetic biology investment the year before that DNA synthesis cost decline: Halving every 18 months or so - Cumbers describes the cost curve for writing DNA Whole genome sequencing cost: A few hundred dollars - Example of falling DNA sequencing costs Scale-up reactor example: 600,000-liter reactor - Used to illustrate industrial manufacturing complexity Earlier reactor example: 500-liter reactor - Contrasted with much larger industrial scale

Pivotal Quotes: "trying to make biology easier to engineer" — John Cumbers: His definition of synthetic biology "what's your bio strategy?" — John Cumbers: The title and central strategic challenge posed to all companies "scale-up continues to be the major issue" — John Cumbers: Discussion of manufacturing and commercialization barriers

Implications: Synthetic biology is moving from niche research toward platform technology with cross-industry impact. Companies that ignore bio-enabled manufacturing, materials, and products may face disruption, while those that invest early could gain a major competitive edge.